Five Phase III Data Readouts To Look Out For In Q2
Crunch Time For Alexion, Aldeyra, Byondis, Novan
Executive Summary
Phase III trials of a number of late-stage investigational therapies are expected to read out during the second quarter of 2021, according to new analysis from Informa Pharma’s product pipeline database Biomedtracker. Some of the Phase III data could be transforming for a few of the less grand players in the pharma sector and here Scrip picks out some of the highlights to look out for in the months ahead.